跳至主要内容
临床试验/DRKS00031548
DRKS00031548招募中4 期

observational comparative study: Intravitreal treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) with a bispecific antibody Vabysmo® (faricimab) vs. a classical anti-VEGF inhibitor Eylea® (aflibercept) in a treat-and-extend-regimen (FATE). - FATE

Augenklinik der Medizinischen Hochschule Hannover0 个研究点目标入组 136 人开始时间: 2023年3月24日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
136

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Consenting patients with macular edema, with underlying cause: neovascular age-related macular degeneration, diabetes mellitus-related maculopathy.
  • Minimum age 18 years, gender male/female/diverse.

排除标准

  • Macular edema caused or influenced by an underlying cause other than neovascular age-related macular degeneration or diabetes mellitus-related maculopathy.
  • lack of capacity to consent.

研究者

发起方
Augenklinik der Medizinischen Hochschule Hannover

相似试验